What is the treatment for otitis media with effusion (OME)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Watchful waiting is the recommended initial approach for otitis media with effusion (OME), as most cases resolve spontaneously within 3 months without intervention. During this period, regular follow-up every 3-6 months is advised to monitor for resolution or complications, as recommended by the most recent guideline 1. Antibiotics, antihistamines, decongestants, and intranasal steroids are generally not recommended for uncomplicated OME as they provide minimal benefit and contribute to antibiotic resistance or other adverse effects 1. If OME persists beyond 3 months with significant hearing loss or recurrent acute otitis media episodes, referral to an otolaryngologist for possible tympanostomy tube placement should be considered, with the decision guided by the child's risk factors and hearing status 1.

Some key considerations in managing OME include:

  • Documenting the presence of middle ear effusion with pneumatic otoscopy when diagnosing OME in a child 1
  • Obtaining tympanometry in children with suspected OME for whom the diagnosis is uncertain after performing pneumatic otoscopy 1
  • Evaluating at-risk children for OME at the time of diagnosis of an at-risk condition and at 12 to 18 months of age 1
  • Counseling families of children with bilateral OME and documented hearing loss about the potential impact on speech and language development 1
  • Recommending tympanostomy tubes when surgery is performed for OME in a child less than 4 years old, with adenoidectomy considered for children 4 years old or older 1

The rationale for watchful waiting stems from the pathophysiology of OME, which typically results from eustachian tube dysfunction causing negative middle ear pressure and fluid accumulation. This condition often resolves as eustachian tube function improves, particularly as children grow and their anatomy develops. Therefore, a period of watchful waiting for 3 months is recommended before considering surgical intervention, unless the child is at increased risk for speech, language, or learning problems due to baseline sensory, physical, cognitive, or behavioral factors 1.

From the Research

Treatment Options for Otitis Media with Effusion

  • Tympanostomy tube insertion with adenoidectomy has been shown to have a significant treatment effect for children with recurrent otitis media with effusion, reducing the recurrent rate after surgery and shortening the time of middle ear cavity effusion 2.
  • Adenoidectomy may be beneficial in treating otitis media in children who are older than 4 years of age and who have previously undergone tympanostomy-tube insertion 3.
  • The American Academy of Otolaryngology-Head and Neck Surgery Foundation recommends tympanostomy tubes when surgery is performed for OME in a child <4 years old, and adenoidectomy should not be performed unless a distinct indication exists 4.
  • For children ≥4 years old, the recommendation is for tympanostomy tubes, adenoidectomy, or both when surgery is performed for OME 4.

Effectiveness of Adenoidectomy and Tympanostomy Tubes

  • Adenoidectomy and tympanostomy tubes have been shown to be effective in reducing the time spent with effusion and improving hearing in children with chronic otitis media with effusion 5.
  • A systematic review of surgical treatments for otitis media with effusion found that tubes and adenoidectomy reduce time with OME and improve hearing in the short-term, but both treatments have associated harms 6.

Recommendations for Management

  • Clinicians should document the presence of middle ear effusion with pneumatic otoscopy when diagnosing OME in a child, and perform pneumatic otoscopy to assess for OME in a child with otalgia, hearing loss, or both 4.
  • Watchful waiting for 3 months from the date of effusion onset or 3 months from the date of diagnosis is recommended for children with OME who are not at risk 4.
  • Clinicians should educate children with OME and their families regarding the natural history of OME, need for follow-up, and the possible sequelae 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Effect of tympanostomy tube insertion with adenoidectomy for children with recurrent otitis media with effusion].

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2016

Research

Adenoidectomy and tympanostomy tubes in the management of otitis media.

Current allergy and asthma reports, 2006

Research

Clinical Practice Guideline: Otitis Media with Effusion (Update).

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2016

Related Questions

What is the diagnosis and treatment for otitis media with effusion (OME)?
How to manage otitis media with effusion without infection?
What is the initial management for a school-aged child with otitis media with effusion (OME) and a mild decrease in hearing?
What is the follow-up protocol for discharge from the clinic for children with Otitis Media (Middle Ear Infection) with Effusion (OME)?
What is the diagnosis and treatment for Otitis Media with Effusion (OME)?
What is the most effective antidepressant medication for treatment-resistant depression?
Does serum bicarbonate level increase with furosemide (Lasix) administration?
What are the potential causes of pruritus (itching) on the feet and ankles without evident dermatitis (rash) or cutaneous lesions?
What is the justification for upadacitinib (Janus kinase inhibitor) therapy in a 55-year-old woman with severe lifelong atopic dermatitis, characterized by high Eczema Area and Severity Index (EASI) scores and significant impairment in Dermatology Life Quality Index (DLQI) scores, who has shown improvement with 15mg daily dosing?
What is the justification for upadacitinib (Rinvoq) therapy in a 55-year-old woman with severe, lifelong atopic dermatitis, characterized by high Eczema Area and Severity Index (EASI) scores and significant impairment in Dermatology Life Quality Index (DLQI) scores, who has failed treatment with methotrexate, azathioprine, mycophenolate, and ciclosporin, and lacks access to biologics like dupilumab (Dupixent)?
When are bilirubin (bilirubin) levels measured in a newborn and how often are they taken?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.